Media Coverage Of Omkar Speciality Chemicals Ltd.

Omkar Speciality Chemicals forays into pharmaceutical business Media Coverage of our company in Bizxwires (12/04/2012)

Omkar Speciality Chemicals has forayed into pharmaceutical business with its recent acquisition of LASA Laboratory located at Mahad in Raigad district, which has been an established player in the anthelmintic/ veterinary API segment with state-of-the‚Äďart API manufacturing facility. This acquisition is strategic for the company in terms of addition of new verticals as well as value addition.

The above acquisition will enable the company to focus on manufacturing anthelmintics, such as Albendazol EP, Albendazole IP/USP, Cyromazine, Fenbendazole, BP VET/ EP, Nitroxynil BP Vet, Ricobendazole, Toldimphos Sodium and Triclabendazole

The API division is already in operations, and will initially focus on continuing the existing API business of LASA Laboratory, which has massive demand in India and abroad. The products are used as anthelmintics or deworming agents for veterinary. Currently, the product portfolio in this division comprises 10 products in the veterinary anthelmentics segment, mainly Benzimidazoles and other active pharma ingredients.

In addition, Omkar Speciality Chemicals has also plans to manufacture APIs with forward integration of some of the key intermediates which are currently being manufactured in the company.

Omkar Speciality Chemicals is mainly engaged in the manufacture and sale of speciality chemicals viz., selenium compounds, iodine compounds, molybdenum compounds etc. and pharma intermediates viz., Potassium Iodate, Bismuth Ammonium Citrate, Bromoform etc.